Flamma, a global Contract Development and Manufacturing Organization (CDMO) focused on small molecule APIs, peptides and advanced intermediates, today announced that it has entered into an agreement to acquire Lundbeck Pharmaceuticals Italy SpA (“LuPI”) from H. Lundbeck A/S (“Lundbeck”). The transaction is subject to customary closing conditions and is expected to close on January 1, 2027.
The acquisition marks another important step in Flamma’s strategic expansion and reinforces the company’s commitment to investing in high-quality pharmaceutical manufacturing infrastructure. Upon completion of the transaction, Flamma will operate four cGMP API manufacturing sites within close proximity to one another in Northern Italy, along with its manufacturing operations in China and in the United States.
The Padova facility contributes up to 220 mÑ of manufacturing capacity, increasing Flamma’s total capacity to approximately 1,100 mÑ in Italy. The site also adds a state-of-the-art API manufacturing workshop, recently approved by AIFA ,together with advanced technological capabilities including hydrogenation, micronization, high-pressure chemistry, hazardous chemistry, and high-containment manufacturing with a longstanding reputation for quality, operational excellence, and the successful development and manufacture of complex APIs.
By combining expanded manufacturing capacity with deep technical expertise, regulatory excellence and a highly experienced workforce, the acquisition further enhances Flamma’s ability to support pharmaceutical innovators from early-stage development through commercial supply. It also advances Flamma’s long-term strategy of building a differentiated global CDMO platform focused on complex small molecule APIs, as well as high-value amino acids and peptides, combining scientific expertise, manufacturing excellence, and supply chain reliability to serve pharmaceutical innovators worldwide.
Lazard is acting as exclusive financial advisor and NCTM Advant as legal advisor to Flamma in connection with the transaction. Canaccord Genuity is acting as exclusive financial advisor and Baker McKenzie as legal advisor to Lundbeck.
Gian Paolo Negrisoli, Chairman of the Board of Directors and CEO of Flamma, said:
“The acquisition of the Padova site represents a strategic investment in Flamma’s growth and in the future of our customers. Beyond the expansion of our manufacturing footprint, we are adding significant scientific, technical and operational capabilities that will strengthen our ability to deliver innovative solutions across the entire pharmaceutical development lifecycle of small molecules and peptides.”
Tine Bryan Stensbøl, interim Head of Product Development & Supply, Lundbeck, said:
“We are very pleased to have found a strong fit with Flamma Group as the new owner of LuPI. Our facility in Padova has a long and proud track record as part of the Lundbeck family, however, Lundbeck’s future need for small molecule manufacturing can expectedly be covered by our facility in Lumsås, Denmark. Consequently, we firmly believe that the decision to divest is the right move for both LuPI and for Lundbeck.”